Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance.
Haematology (incl blood transfusion)
Oncology
Journal
BMJ case reports
ISSN: 1757-790X
Titre abrégé: BMJ Case Rep
Pays: England
ID NLM: 101526291
Informations de publication
Date de publication:
08 Apr 2022
08 Apr 2022
Historique:
entrez:
9
4
2022
pubmed:
10
4
2022
medline:
13
4
2022
Statut:
epublish
Résumé
BRAF V600E mutations are detected in 3%-10% of patients with multiple myeloma (MM) and are associated with more aggressive disease, higher frequency of extramedullary growth and shorter survival. Monotherapy with the BRAF inhibitor vemurafenib has been disappointing in MM. In patients with BRAF-mutated melanoma, MEK and BRAF inhibition has been a successful approach. Here we describe a very good partial response and possible mechanisms of resistance to a combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib in a patient with BRAF V600E-mutant refractory MM.
Identifiants
pubmed: 35396243
pii: 15/4/e246264
doi: 10.1136/bcr-2021-246264
pmc: PMC8996037
pii:
doi:
Substances chimiques
Imidazoles
0
Oximes
0
Protein Kinase Inhibitors
0
Pyridones
0
Pyrimidinones
0
trametinib
33E86K87QN
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Mitogen-Activated Protein Kinase Kinases
EC 2.7.12.2
dabrafenib
QGP4HA4G1B
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© BMJ Publishing Group Limited 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Case Rep Hematol. 2020 Oct 15;2020:8894031
pubmed: 33123389
Biochim Biophys Acta. 2007 Aug;1773(8):1263-84
pubmed: 17126425
Melanoma Res. 2018 Apr;28(2):96-104
pubmed: 29232304
JCO Precis Oncol. 2018 Aug 31;2:
pubmed: 32913989
Oncogenesis. 2017 May 15;6(5):e337
pubmed: 28504689
Hematol Oncol. 2017 Dec;35(4):890-893
pubmed: 27641727
Cancer Cell. 2014 Jan 13;25(1):91-101
pubmed: 24434212
Cancer Discov. 2013 Aug;3(8):862-9
pubmed: 23612012
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Lancet. 2009 Jul 25;374(9686):324-39
pubmed: 19541364
Blood. 2012 Aug 2;120(5):1067-76
pubmed: 22498740
Lancet. 2012 Jul 28;380(9839):358-65
pubmed: 22735384
N Engl J Med. 2014 Nov 13;371(20):1867-76
pubmed: 25265494